Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622

NCT03306043 is registered in ClinicalTrials.gov with GlaxoSmithKline as lead sponsor.

NCT NCT03306043
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03306043 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-centre, Open-label Extension, Safety Study to Describe the Long-term Clinical Experience of Mepolizumab in Participants With Hypereosinophilic Syndrome (HES) From Study 200622
Lead sponsor
GlaxoSmithKline
Phase
Phase 3
Overall status
Completed
Start date
November 13, 2017
Completion date
December 30, 2019
Enrollment
102 (actual)
Sites
36

Conditions

As the registry lists them; a condition with its own page is linked.

hypereosinophilic syndrome